Search Results

Biopharma companies won’t fully capture the benefits of AI unless they reorganize their R&D units, according to McKinsey.

The U.S. government has argued that it pays too much of biopharma R&D costs, demanding that other high-income countries contribute fairly to global innovation efforts.

About two months into CEO Belén Garijo’s new tenure, Sanofi’s R&D chief has departed, with Xaira’s chief medical officer set to take charge of the pharma’s pipeline.

Biotech R&D job postings live on BioSpace rose for the fourth straight month in April, and a CBRE report shared similar findings for employment. The head of CBRE’s U.S. life sciences practice discusses what’s behind the growth and the current job market.

Drug discovery teams have more data than ever, but turning that data into actionable insight remains a major challenge. In this candid conversation, Patsnap’s Ben Coverdale is joined by Mark Davies, Head of Product for Life Sciences, and James Longden, Senior Director, Life Sciences at Evolvus to explore how AI-powered intelligence is reshaping candidate optimization across antibodies, ADCs, and peptides.